We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




New Comprehensive Blood Safety Portfolio Launched at Arab Health 2014

By LabMedica International staff writers
Posted on 04 Feb 2014
A first in the Middle East, a comprehensive blood-screening portfolio from a single source provides advanced serology screening and nucleic acid testing (NAT) technologies at blood centers, enhancing health standards in the region.

Roche Diagnostics Middle East (RDME), of the Roche company (Basel, Switzerland), has now launched the "Roche Blood Safety Solution" (RBSS) at the 2014 Arab Health Congress (Dubai, UAE), the largest healthcare exhibition and education congress in the Middle East. The RBSS portfolio, the first of its kind in the region, delivers reliability and workflow efficiency for Middle East blood centers, reaffirming RDME’s dedication to providing first class diagnostics in the region.

RBSS now enables patients and communities in the region to benefit from a dedicated, safe and efficient, reliable blood supply. The blood supply is made safe by a reduction in manual steps as well as excellent state-of-the-art assay sensitivity and genotype coverage. With technologies such as electrochemiluminescence (ECL) and polymerase chain reaction (PCR), laboratories benefit from high specificity and NAT real-time-target-discrimination. The systems provide the highest reliability available, excellent traceability and cross-contamination control, and less downtime.

Roche is the first IVD company to have a management center and a logistics hub in the Middle East, enabling RDME to develop from being a regional supplier into becoming a local IVD partner for its customers. The RBSS portfolio safeguards patients through leading technologies with dedication to, and investment in, the safety of the world’s blood supply. “Owing largely to our dedication to safeguard the world’s blood supply through technological innovations and drug development, Roche Diagnostics has become the preferred partner in the Blood Bank Industry,” said Michael Heuer, President of Europe, Middle East, Africa, and Latin America at Roche Diagnostics.

“RBSS benefits from the design, support, and streamlined supply chain that you would associate with [Roche]. We are proud to bring RBSS to the Middle East,” added Moritz Hartmann, General Manager of Roche Diagnostics Middle East. Roche offers service and support for reliability in all its workflow solutions, including the RBSS blood-screening platform, with dependable systems that help blood centers enhance workflow efficiency, minimizing processing time. The RBSS workflow solution is driving the concept of automation and setting new industry standards in diagnostic testing. Molecular testing processes will be brought together in a highly automated solution, without the need for manual transfer steps and with results calculated automatically and sent to the laboratory information system. The ease of operation coupled with ease of training result in staff competent in the use of RBSS systems. Furthermore, support structures in the Middle East help ensure operation of the systems with less downtime.

Related Links:

Roche 
Arab Health Congress



Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Community-Acquired Pneumonia Test
RIDA UNITY CAP Bac
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.